German Biotech MAB Discovery Inks Two Deals For Its Rabbit-Derived Antibody Technology
This article was originally published in The Pink Sheet Daily
German antibody services company MAB Discovery – forged by former Roche employees – has had its rabbit antibody-derived technology validated by two collaborative agreements with pharma and biotech companies.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.